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Objectives: Price erosion is considered the key success criterion of generic 
drug policies. For chronic drug therapy, however, persistence with the original 
drug substance is equally important. Low persistence may result in poor health 
outcomes, lead to increased health care costs. Our objective was to estimate the 
impact of switching drug therapy on health and economic outcomes as a conse-
quence of the Hungarian drug policy in hypertension. MethOds: We retrieved 
4-year medical records of hypertensive patients, who had at least 10 prescriptions 
of original losartan or losartan HCT in the 12 months prior to patent expiry. We 
allocated patients to 3 groups based on switching history in the 12 months after 
patent expiry. Group 1 patients were switched to another patented antihyperten-
sive product without risk for generic substitution (n= 953). Group 2 patients were 
switched to generic losartan or losartan HCT, but did not change the generic brand 
in 12 months (n= 630). Group 3 patients were switched at least twice among differ-
ent generic brands in 12 months (n= 1144). We calculated the incidence of major 
cardiovascular events (MACE) and overall health care cost (289.42 HUF/EUR 2012 
average exchange rate) in each group. Results: Total 3-year health care costs were 
€ 9,728, € 6,594, € 8,227, the incidence of MACEs was 13.3%, 9.8%, 12.3% in Group 1, 2 
and 3 respectively. cOnclusiOns: In chronic diseases switching to generic drugs 
reduces health care costs. However, frequent switching among generic brands may 
result in negative health outcomes and increased health care costs. Suboptimal 
implementation of generic drug policies in chronic diseases may compromise 
expected benefits (i.e. same health gain at lower costs). Potential confounding fac-
tors may limit the generalizability of our conclusions.
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Objectives: There are two important success criteria of generic drug policies in 
chronic diseases after patent expiry: price erosion and persistence. Our objective 
was to assess the implementation of generic drug policies on these criteria between 
2007-2011 in Hungary by comparing the continuation of angiotensin receptor block-
ers after patent expiry of original therapies. MethOds: In Hungary the first generic 
losartan was launched in 2007; losartan HCT in 2009; valsartan/valsartan HCT in 
2011. From the National Health Insurance Fund database, we selected prescription 
records of hypertensive patients with at least 10 prescriptions of original losar-
tan (Group 1; n= 2637), losartan HCT (Group 2; n= 7598) and valsartan/valsartan 
HCT (Group 3; n= 38098) in the last 12 months prior to patent expiry. We compared 
antihypertensive therapies in 12 months after the reimbursement of first generic 
drug in each group. Antihypertensives were categorized into preferred (continued 
antihypertensive therapy with same active ingredient generic drugs), and non-pre-
ferred (continuation on original drug therapy; switching to other patented drug(s) 
without risk for generic substitution; switching to generic drugs with other active 
ingredient(s); discontinuation of reimbursed antihypertensive drug therapies) policy 
outcomes. Results: After patent expiry 76.2% and 68.9% of Group 1&2 patients 
continued the original losartan or losartan HCT therapy for 12 months, and only 
3.9% and 8.5% were switched to generic losartan/losartan HCT. In Group 3, 33.6% 
of patients were switched to generic valsartan/valsartan HCT, 42.8% received other 
generic drugs or drug combinations, whilst 14.5% were switched to other patented 
products. cOnclusiOns: Despite significant changes in the generic drug policies 
in Hungary in 2007, 2009 and 2011 not more than one-third of hypertensive patients 
changed to generic drugs during 12 months after first generic entry. These findings 
indicate suboptimal generic drug policy in a chronic disease with significant public 
health implications.
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Objectives: To review the consumption pattern of ambulatory high expenditure 
therapeutic groups in Portugal following prescribing guidelines set forth by the 
Memorandum of Understanding; to perform a cross-country comparison of utili-
zation patterns focusing on quality prescribing indicators identified by the EURO-
MED-STAT and/or major international prescribing guidelines; and to perform a 
cost-saving scenario analysis if more rational European prescribing patterns were 
undertaken in Portugal. MethOds: Cross-national drug utilization study with 
data from seven European countries: Portugal, Denmark, England, Finland, The 
Netherlands, Norway and Sweden. Data from Portugal retrieved from hmR Pharmacy 
Sales Information System, a nationwide database with representative pharmacy 
dispensing data. Data from other countries was selected from published literature 
and/or public databases. Cost-saving analysis with assumptions: average annual 
cost per defined daily dose (DDD) from Portugal and simulations to measure the 
impact on total expenditure of international utilization patterns (DDD proportion) 
versus Portuguese pattern. Results: Portugal has the highest consumption of 
oral antidiabetic combinations (19.3% in 2010), of Antagonists Reception Blockers 
(ARBs) (31% in 2009), and of rosuvastatin (22.2% in 2011). A total of 236 Million euro 
annual cost-savings was estimated in scenarios of more rational prescribing: 100 
Million euro (58% decrease in costs of antidiabetic agents in 2010) when simulating 
the Dutch oral antidiabetic prescribing pattern; 106 Million euro when simulating 
the Danish antihypertensive prescribing pattern (20% decrease in antihypertensive 
costs in 2009); and 26 Million euro when simulating the UK statin prescribing pat-
tern (13% decrease in statin costs in 2011). cOnclusiOns: It is crucial to optimize 
prescribing patterns in Portugal, in order to achieve a more rational use of medi-
cines and a sustained control of pharmaceutical expenditure. Besides prescribing 
Objectives: To review the literature about adherence to warfarin treatment 
in Brazil. MethOds: A systematic review of the literature and a wide search 
in LILACS (Literatura Latino Americana e do Caribe em Ciências da Saúde) and 
MEDLINE (Medlars On Line) electronic databases were conducted to identify 
studies with the key words: “warfarin” and “Brazil”. The combination of terms 
was used as reference for the analysis. Search was restricted to randomized con-
trolled trials (RCT), systematic reviews, meta-analysis and prospective clinical 
trials (PCT). Results: A total of 77 studies were identified, from which only 22 
met inclusion criteria: 1 meta-analysis, 5 RCTs, 8 systematic reviews and 8 PCTs. 
Only 1 study described adherence to treatment. From a total of 229 randomized 
patients, 119 received warfarin. Adherence to treatment was observed in 42% 
(p= 0.001) of patients using warfarin considering an average of 57+-18 months 
of follow-up, INR < 2 in 37.54 % and INR > 2 in 11.18 %. Multivariate analysis 
estimated that every 1% of INR < 2, the risk of a thromboembolic event increases 
8.4%. cOnclusiOns: The systematic review of the literature showed lack of 
data regarding Brazilian patients under warfarin treatment. The only available 
study did not define adherence and it did not investigate the underlying causes 
of non-adherence. Thus, it is recommended the conduction of further studies 
in order to provide better understanding of anticoagulant therapies compliance 
in Brazilian patients.
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Objectives: Potentially avoidable hospitalizations (PAH) are increasing in Spain 
and account for more than 3% of all the discharges. One of the hypothesis to 
explain PAH lies on the suboptimal management of chronic disease at ambulatory 
level of care. In this study we aim at explaining the association between compli-
ance with preventive recommendations in primary care and observed rate of 
PAH. MethOds: Compliance with evidence-based preventive recommendations 
regarding diabetes mellitus (DM), chronic heart failure (CHF) and chronic obstruc-
tive pulmonary disease (COPD) was calculated for the 1,350 general practition-
ers of the Basque Health Service and compared with the annual (2011) observed 
rate of PAH between their patients’ panel (mean panel≈1,500 adults; population 
covered= 1,942,873). PAH was defined by a restrictive set of ICD-9 criteria follow-
ing recommendations of the Spanish group of studies on Variability in Medical 
Practice. Multilevel poisson regression was used and age, sex, status socioeco-
nomic (SSE) and hospital of reference were entered as covariates. Results: After 
adjusting by all the covariates, higher compliance of recommendations such as 
periodical spirometry or assessment of the correct use of bronchodilator inhalers 
shows association with lower rates of PAH by COPD (p< 0.05). Periodical foot care, 
oftalmological exam or assessment of the cardiovascular risk is non-significantly 
(0.15≥ p≥ 0.05) but consistently associated to lower rates of PAH by DM. No link was 
observed between compliance or recommendations for CHF and PAH due to this 
cause. The independent effect of the SSE was strong in all the diseases (p< 0.001) 
(higher rates as privation increases). Variations regarding the hospital of refer-
ence were also observed. cOnclusiOns: Adequate compliance of evidence-based 
recommendations limits, modestly but consistently, the incidence of PAH due to 
DM or COPD. The SSE and the hospital of reference explain part of the observed 
variability in hospitalization by chronic disease.
PCV146
VAlue ChAin AnAlysis for CArDiAC DeViCes
Lucas F.1, Tsai P.2
1Pope Woodhead and Associates, St. Ives, UK, 2Cambridge University, Cambridge, UK
Objectives: We investigated opportunities to cost-effectively improve health out-
comes for patients eligible for ICD, sICD and CRT-D devices. This area was chosen 
because of the high cost of these devices and the significant amount of uncertainty 
on how to use them in a cost effective way. Also, we aimed to explore value-added 
services to patients and physicians, and the area appeared to have potential for 
this. MethOds: We conducted a value chain analysis. The first step was to clarify 
the care pathway and identify places where outcome or efficiency were poor; the 
second step was to prioritise the associated problems based on their importance 
(health/cost impact) and the feasibility of addressing the root causes in the short to 
medium term; the third step was to propose ways to address the priority problems 
and add value in the care pathway. To do this, we conducted secondary research, and 
primary research mainly focused on the UK (20 in-depth discussions with cardiolo-
gists, patients and manufacturers). Results: A core issue was the lack of good evi-
dence-based criteria to identify which patients would benefit most from the various 
devices. Referral to device implantation and funding were seen as below the levels 
expected given current clinical and HTA guidelines; the gap might even increase 
given the expectation that future guidelines may call for higher implantation rates. 
The proposed solutions focused on increasing awareness of the guidelines for more 
effective referral to specialist centres, supporting more flexibility in local funding, 
and taking advantage of the rich, continuous data that the devices themselves could 
provide with a view to eventually improve eligibility criteria. cOnclusiOns: It 
is increasingly difficult to achieve health gains through new therapies. Therefore, 
focusing on improving referral and delivery pathways of current therapies may be 
quite effective at increasing health gains and/or efficiency.
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were on polytherapy, 41% on monotherapy, and 4% had no antihypertensive treat-
ment. Polytherapy was more predominant with age, duration of diabetes, duration of 
hypertension, and comorbid complications. cOnclusiOns: Although prescribing 
pattern of antihypertensive showed adherence to existing evidence-based guide-
lines, higher proportion of uncontrolled hypertensive patients was found.
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Objectives: Patients undergoing initial therapeutic anticoagulation after a venous 
thromboembolic event (VTE) with severely impaired renal function (RI-VTE-patients) 
are at high risk of accumulating the anticoagulants resulting in an increased risk of 
bleeding events. Current guidelines/approved summary of product characteristics 
(SPC) recommend usage of specific anticoagulants only, monitoring of aXa-activity, 
and/or dose-adjustment (in the case of enoxaparin) for initial therapeutic anticoagu-
lation of RI-VTE-patients. This study investigates the treatment of German RI-VTE-
patients and evaluates whether guideline/SPC recommendations are implemented 
in the practice of real life care. MethOds: We conducted a chart review in 5 German 
hospitals. All VTE patients treated in these hospitals from 01/01/2007-31/12/2011 
were included. RI was defined as CrCl< 30ml/min. Treatment did not conform to the 
recommendations in guidelines/SPCs, if: a) A drug was used that is contraindicated 
according to the SPC; b) The recorded daily dose of enoxaparin was higher than the 
recommended weight-adjusted dose. Results: Of 5,263 VTE patients identified, 709 
(13.5%) cases could not be documented due to missing charts (601) or no documented 
creatinine serum levels (108). Of the remaining 4,554 patients (mean age ±SD 67.4 
years ±15.7; 53.0% female; weight 80.2 kg ±20.0; 54.5% deep VT), 337 (7.4%) had a mean 
estimated GFR< 30ml/min; additionally 1,630 (35.8%) had a minimum eGFR< 60ml/
min. In 19 (5.6%) of these cases, patients were treated with a drug not recommended 
for use, 21 (6.2%) did not receive any initial anticoagulation treatment and 91 (27.0%) 
received a higher than recommended dosage of enoxaparin. Additionally, for 22 
patients (6.5%) receiving enoxaparin, no weight information was recorded and it 
is therefore unlikely that the dosage was adjusted correctly. cOnclusiOns: VTE 
treatment in RI-VTE-patients differs remarkably from labelled recommendations; 
over-dosage of enoxaparin is common. It seems fair to assume that these patients are 
facing a higher risk of adverse reactions in particular bleeding events.
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Objectives: To determine the attitude of physicians in three family medicine centers 
(FMCs) at the National Guard Health Affairs (NGHA) toward the implementation of 
the Shared Medical Appointment (SMA) approach compared to the current individual 
appointment approach. MethOds: A cross-sectional survey study was conducted 
by distributing a structured questionnaire among the 79 FMCs’ physicians at NGHA 
in Riyadh, Saudi Arabia. The first part of the questionnaire was an introduction, the 
second part has requested socio-demographic information, and the third part con-
sisted of 12 statements measuring physicians’ attitude toward implementing SMA 
and the current individual appointment approach. Responses were measured using 
5-points Likert Scale. Seventy-nine self-administered questionnaires were distributed 
to physicians’ mail-boxes and the completed questionnaires were collected from 
mail-boxes at each clinic. Data collection was done from December 10 to 15, 2011. 
Data were entered and analyzed by the Statistical Package for Social Science (SPSS.16). 
Descriptive analysis was conducted using frequencies, percentages, and mean (SD). 
Inferential analysis was conducted using one way ANOVA and Mann-Whitney tests 
to detect statistically significant differences in responses. A significance level of 
0.05 was used. The validity and reliability of the instrument was measured using 
Pearson’s correlation and Cronbach’s Alpha, respectively. Results: A totla of 78 valid 
questionnaires were returned yielding a response rate of 99 %. The average attitude 
scores were 3.75 toward the SMA approach and 2.98 toward the current Individual 
Appointment approach. The average attitude scores were significantly different at all 
dimensions (Mann Whtiney P-value < 0.001) in favor of SMA except for patient privacy 
which was in favor of current individual appointment approach. Subgroup analysis by 
socio-demographic variables indicated that males and Saudi national physicians have 
higher positive attitude toward SMA. cOnclusiOns: There is positive attitude of all 
physicians toward SMA compared to the current individual appointment approach. 
This attitude was affected by gender and nationality.
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Objectives: To assess the re-hospitalisations rates for stroke (ST) and transient 
ischemia (TI) recurrences as well as related inpatient costs through the French 
national Hospitals Medical Health Information database (PMSI). MethOds: A ret-
rospective hospital administrative-claims analysis was carried out based on the 
Diagnoses Related Groups (DRG)-data of four hospitals within the Burgundy region 
along the 2006-2011 period. In each of the four hospitals, three cohorts were fol-
lowed up over two years. Patients were excluded if any related hospitalisation for ST 
or TI occurred in the preceding two-years (identification through ICD-10 diagnosis 
codes). One and two-year re-hospitalisations rates for ST and/or IT were calculated. 
guidelines, health prevention / monitoring strategies, involving coordinated actions 
between primary care and pharmacies, are valuable resources to consider.
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Objectives: The Ukrainian government has been considering ways to improve the 
population’s access to medicines by offering limited reimbursement access. For this 
purpose, the government has expressed its interest in implementing International 
reference pricing (IRP). The pilot hypertension programme, which introduced a sys-
tem of IRP for certain hypertension drugs, was introduced in mid-2012. The govern-
ment is currently looking to revise the pricing and reimbursement mechanism and 
to expand the list of drugs eligible for reimbursement under the scheme. This study 
examines the pilot hypertension programme and its impact in terms of achieving its 
objectives so far. MethOds: Secondary research focused on analysing the current 
pharmaceutical market and health care situation in Ukraine, with a specific focus on 
the hypertension market. The study then assessed the pricing and reimbursement 
methodology which is currently in place, the programme’s objectives, and its impact 
on volume and value of the antihypertensives market. Results: Hypertension 
was chosen for the pilot programme due to the high prevalence of the condition in 
the country. While, for the full year 2012, the weighted average cost per package in 
the antihypertensive drug segment decreased by 1.4% compared to the previous 
year, the volume of retail sales increased 16.8%. Furthermore, as of January 2013, 
the prices of these drugs had been falling every month from July till December 
2012 compared to the corresponding months of 2011. cOnclusiOns: With the 
pilot hypertension programme, the government is hoping to lower drug prices and 
thereby improve affordability. Considering that the pilot scheme could be followed 
by programmes in other therapeutic areas, including a government proposal to 
include IRP for insulin treatments, the structure and effectiveness of the hyperten-
sion programme, and the subsequent amendments to it, could substantially impact 
the development of any other potential programmes in the future.
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Objectives: This paper constitutes an attempt at investigating processes of 
dynamic competition in pharmaceuticals, with reference to the nature and intensity 
of price competition in relation to patent expiry and different regulatory regimes. 
The paper uses comprehensive data on a selection of in-patent and off-patent 
(generic) cardiovascular medicines from IMS from the five largest European phar-
maceutical markets - UK, Germany, France, Italy, Spain - to analyze the impact that 
pricing and reimbursement regulation and product differentiation have on market 
structure, diffusion and prices. MethOds: The paper develops a panel data model 
to explain the determinants of brand-name prices and generic prices both before 
and after patent expiry, the impact of generic entry and generic penetration on 
market share and prices of brand-name drugs, the competition patterns in their 
off-patent sector, the determinants of generic diffusion in the presence of generic 
competition, and the relationship between originator branded and generic prices 
under different regulatory regimes. The structure of the data allows these ques-
tions to be explored at molecule level and at product level. At all levels the origi-
nator and generic markets are observable. Results: Despite the proliferation of 
generic policies in many countries, prices in the off-patent sector do not decline as 
fast as originally thought. Entry into the generic market is positively influenced by 
regulation through reference pricing and opportunities for product differentiation. 
Elements of product differentiation within generics promote diffusion, but do not 
reduce prices. And, health insurance does not capitalize fully on the cost advantage 
of generic medicines. cOnclusiOns: The results suggest that the relationships 
between the dynamics of original drug prices, patent expiry, and generic competi-
tion are complex and differentiated across countries. The level of generic penetra-
tion remains low in some of them and a sharp contrast exists between countries.
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Objectives: Hypertension management is of a paramount importance in diabetic 
patients for cardiovascular risk reduction. Hence, we evaluated prescribing pattern 
of antihypertensive in T2DM (type 2 diabetes) patients and compare with existing 
recent guidelines. MethOds: A cross-sectional study involving evaluation of all 
T2DM patients referred to endocrinology unit at tertiary care centre for hyperten-
sion, comorbid complications, and recording prescription. Utilization of 5 different 
antihypertensive drug classes was compared for all patients receiving 1, 2, 3, 4, or 
more drugs. Logistical regression was used to assess likelihood of prescription of 
drugs and/or therapy for specific conditions mentioned in the guidelines. Results: 
Out of 1358, T2DM enrolled patients 1186 (87%) had hypertension (males 52%, 
females 48%). The median duration (IQ) of hypertension diabetics was 4 (1-10) years. 
A total of 25% patients had controlled BP and 75% with uncontrolled blood pressure 
(13% isolated systolic hypertension, 6% isolated diastolic hypertension, and 55% 
both elevated). Overall, ACE inhibitors (ACEIs) were prescribed the highest (59%) 
followed by angiotensin receptor blockers (ARBs) (52%), calcium channel blockers 
(CCBs) (29%), diuretics (27%), and beta-blockers (14%). Overall, 55% of T2DM patients 
